Nanosystem functionalization strategies for prostate cancer treatment : a review
Prostate cancer (PC) has a high morbidity and mortality rate worldwide, and the current clinical guidelines can vary depending on the stage of the disease. Drug delivery nanosystems (DDNs) can improve biopharmaceutical properties of encapsulated anti-cancer drugs by modulating their release kinetics, improving physicochemical stability and reducing toxicity. DDN can also enhance the ability of specific targeting through surface modification by coupling ligands (antibodies, nucleic acids, peptides, aptamer, proteins), thus favouring the cell internalisation process by endocytosis. The purposes of this review are to describe the limitations in the treatment of PC, explore different functionalization such as polymeric, lipid and inorganic nanosystems aimed at the treatment of PC, and demonstrate the improvement of this modification for an active target, as alternative and promising candidates for new therapies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Journal of drug targeting - 29(2021), 8 vom: 16. Sept., Seite 808-821 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
de Araújo, Jennifer Thayanne Cavalcante [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Active target |
|---|
| Anmerkungen: |
Date Completed 10.01.2022 Date Revised 10.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/1061186X.2021.1892121 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32203230X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32203230X | ||
| 003 | DE-627 | ||
| 005 | 20231225181152.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/1061186X.2021.1892121 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1073.xml |
| 035 | |a (DE-627)NLM32203230X | ||
| 035 | |a (NLM)33645369 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a de Araújo, Jennifer Thayanne Cavalcante |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nanosystem functionalization strategies for prostate cancer treatment |b a review |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.01.2022 | ||
| 500 | |a Date Revised 10.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Prostate cancer (PC) has a high morbidity and mortality rate worldwide, and the current clinical guidelines can vary depending on the stage of the disease. Drug delivery nanosystems (DDNs) can improve biopharmaceutical properties of encapsulated anti-cancer drugs by modulating their release kinetics, improving physicochemical stability and reducing toxicity. DDN can also enhance the ability of specific targeting through surface modification by coupling ligands (antibodies, nucleic acids, peptides, aptamer, proteins), thus favouring the cell internalisation process by endocytosis. The purposes of this review are to describe the limitations in the treatment of PC, explore different functionalization such as polymeric, lipid and inorganic nanosystems aimed at the treatment of PC, and demonstrate the improvement of this modification for an active target, as alternative and promising candidates for new therapies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cancer therapy | |
| 650 | 4 | |a active target | |
| 650 | 4 | |a drug delivery system | |
| 650 | 4 | |a ligand-specific | |
| 650 | 4 | |a prostate cancer | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Duarte, Jonatas Lobato |e verfasserin |4 aut | |
| 700 | 1 | |a Di Filippo, Leonardo Delello |e verfasserin |4 aut | |
| 700 | 1 | |a Araújo, Victor Hugo Sousa |e verfasserin |4 aut | |
| 700 | 1 | |a Carvalho, Gabriela Corrêa |e verfasserin |4 aut | |
| 700 | 1 | |a Chorilli, Marlus |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of drug targeting |d 1996 |g 29(2021), 8 vom: 16. Sept., Seite 808-821 |w (DE-627)NLM074733958 |x 1029-2330 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2021 |g number:8 |g day:16 |g month:09 |g pages:808-821 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/1061186X.2021.1892121 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2021 |e 8 |b 16 |c 09 |h 808-821 | ||